1887

Chapter 2 : Human Immunodeficiency Virus

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.
  • HTML
    123.40 Kb
  • XML
    151.16 Kb
  • PDF
    472.81 Kb

Preview this chapter:
Zoom in
Zoomout

Human Immunodeficiency Virus, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555819040/9781555819033_Chap02-1.gif /docserver/preview/fulltext/10.1128/9781555819040/9781555819033_Chap02-2.gif

Abstract:

The human immunodeficiency viruses type 1 (HIV-1) and 2 (HIV-2) are enveloped RNA viruses that are members of the genus and the family Retroviridae. HIV-1 is further divided into four groups; three of these originated from chimpanzee simian immunodeficiency virus and are designated group M (major)—responsible for the majority of the worldwide epidemic, group O (outlier), and group N (nonmajor and nonoutlier). Each group phylogenetically correlates with three separate transmission events ( ). The fourth, group P, has been recently identified and is closely related to a gorilla simian immunodeficiency virus ( ). Within group M there are nine different subtypes and more than 40 circulating recombinant forms (CRFs), which together lead to enormous viral genetic diversity. This variability plays an important role in the design and interpretation of viral load and resistance assays, and it provides clues to epidemiology and transmission of HIV-1. HIV-2 is a much smaller epidemic than HIV-1 and has its origins in simian immunodeficiency virus sooty mangabey () with at least eight distinct transmissions to humans. Correct diagnosis of HIV-1 versus HIV-2 is critical as there are distinct differences in response to antiretroviral therapy.

Citation: Armstrong W, Guarner J, Kraft C, Caliendo A. 2016. Human Immunodeficiency Virus, p 53-68. In Hayden R, Wolk D, Carroll K, Tang Y (ed),

Diagnostic Microbiology of the Immunocompromised Host, Second Edition

. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.DMIH2-0024-2015
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

/deliver/fulltext/10.1128/9781555819040/chap2.html?itemId=/content/book/10.1128/9781555819040.chap2&mimeType=html&fmt=ahah

Figures

Image of Figure 1

Click to view

Figure 1

Life cycle of HIV-1. Reprinted from reference , with permission.

Citation: Armstrong W, Guarner J, Kraft C, Caliendo A. 2016. Human Immunodeficiency Virus, p 53-68. In Hayden R, Wolk D, Carroll K, Tang Y (ed),

Diagnostic Microbiology of the Immunocompromised Host, Second Edition

. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.DMIH2-0024-2015
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 2

Click to view

Figure 2

Timeline for detection of virus using different assays, as compared to Western blot.

Citation: Armstrong W, Guarner J, Kraft C, Caliendo A. 2016. Human Immunodeficiency Virus, p 53-68. In Hayden R, Wolk D, Carroll K, Tang Y (ed),

Diagnostic Microbiology of the Immunocompromised Host, Second Edition

. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.DMIH2-0024-2015
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 3

Click to view

Figure 3

CDC and Association of Public Health Laboratories guideline for diagnosis of HIV infection.

Citation: Armstrong W, Guarner J, Kraft C, Caliendo A. 2016. Human Immunodeficiency Virus, p 53-68. In Hayden R, Wolk D, Carroll K, Tang Y (ed),

Diagnostic Microbiology of the Immunocompromised Host, Second Edition

. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.DMIH2-0024-2015
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555819040.chap2
1. Gao F,, Bailes E,, Robertson DL,, Chen Y,, Rodenburg CM,, Michael SF,, Cummins LB,, Arthur LO,, Peeters M,, Shaw GM,, Sharp PM,, Hahn BH . 1999. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes . Nature 397 : 436 441.[CrossRef]
2. Sharp PM,, Bailes E,, Chaudhuri RR,, Rodenburg CM,, Santiago MO,, Hahn BH . 2001. The origins of acquired immune deficiency syndrome viruses: where and when? Philos Trans R Soc Lond B Biol Sci 356 : 867 876.[CrossRef]
3. Hunter E, . 2008. Retroviruses, p 680. In Mahy BWJ, and van Regenmortel MHV (ed), Encyclopedia of Virology, 3rd ed. Elsevier, Amsterdam. [CrossRef]
4. Ronen K,, Sharma A,, Overbaugh J . 2015. HIV transmission biology: translation for HIV prevention. AIDS 29 : 2219 2227.[CrossRef]
5. Patel P,, Borkowf CB,, Brooks JT,, Lasry A,, Lansky A,, Mermin J . 2014. Estimating per-act HIV transmission risk: a systematic review. AIDS 28 : 1509 1519.[CrossRef]
6. Eshleman SH,, Hudelson SE,, Ou SS,, Redd AD,, Swanstrom R,, Porcella SF,, Chen YQ,, Piwowar-Manning E,, McCauley M,, Gamble T,, Sievers M,, Martens CA,, Bruno D,, Ping L-H,, Dukhovlinova E,, Quinn TC,, Kumwenda J,, Madiwichi M,, Nhando N,, Akelo V,, Moyo S,, Panchia R,, Kumarasamy N,, Chotirosniramit N,, Rocha MM,, Bustorff F,, Brinsztejn B,, Mayer KH,, Hughes JP,, Cohen MS for the HPTN O52 Study Team . 2015. Treatment as prevention: characterization of partner infections in the HIV Prevention Trials Network 052 trial. Program number MOAC0106LB, 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Vancouver, Canada.
7. Douek D . 2007. HIV disease progression: immune activation, microbes, and a leaky gut. Top HIV Med 15 : 114 117.
8. Mellors JW,, Muñoz A,, Giorgi JV,, Margolick JB,, Tassoni CJ,, Gupta P,, Kingsley LA,, Todd JA,, Saah AJ,, Detels R,, Phair JP,, Rinaldo CR Jr . 1997. Plasma viral load and CD4 + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 126 : 946 954.[CrossRef]
9. Rodger AJ,, Lodwick R,, Schechter M,, Deeks S,, Amin J,, Gilson R,, Paredes R,, Bakowska E,, Engsig FN,, Phillips A , Insight Smart ESG, INSIGHT SMART, ESPRIT Study Groups . 2013. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS 27 : 973 979.[CrossRef]
10. Locke JE,, Durand C,, Reed RD,, MacLennan PA,, Mehta S,, Massie A,, Nellore A,, DuBay D,, Segev DL . 2016. Long-term outcomes after liver transplantation among human immunodeficiency virus-infected recipients. Transplantation 100 : 141 146.[CrossRef]
11. Locke JE,, Mehta S,, Reed RD,, MacLennan P,, Massie A,, Nellore A,, Durand C,, Segev DL . 2015. A national study of outcomes among HIV-infected kidney transplant recipients. J Am Soc Nephrol 26 : 2222 2229.[CrossRef]
12. Stock PG,, Barin B,, Murphy B,, Hanto D,, Diego JM,, Light J,, Davis C,, Blumberg E,, Simon D,, Subramanian A,, Millis JM,, Lyon GM,, Brayman K,, Slakey D,, Shapiro R,, Melancon J,, Jacobson JM,, Stosor V,, Olson JL,, Stablein DM,, Roland ME . 2010. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med 363 : 2004 2014.[CrossRef]
13. Muller E,, Barday Z,, Mendelson M,, Kahn D . 2015. HIV-positive-to-HIV-positive kidney transplantation—results at 3 to 5 years. N Engl J Med 372 : 613 620.[CrossRef]
14. Hütter G,, Nowak D,, Mossner M,, Ganepola S,, Müssig A,, Allers K,, Schneider T,, Hofmann J,, Kücherer C,, Blau O,, Blau IW,, Hofmann WK,, Thiel E . 2009. Long-term control of HIV by CCR5 delta32/delta32 stem-cell transplantation. N Engl J Med 360 : 692 698.[CrossRef]
15. Henrich TJ,, Hanhauser E,, Marty FM,, Sirignano MN,, Keating S,, Lee TH,, Robles YP,, Davis BT,, Li JZ,, Heisey A,, Hill AL,, Busch MP,, Armand P,, Soiffer RJ,, Altfeld M,, Kuritzkes DR . 2014. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med 161 : 319 327.[CrossRef]
16. Durand CM,, Ambinder RF . 2013. Hematopoietic stem cell transplantation in HIV-1-infected individuals: clinical challenges and the potential for viral eradication. Curr Opin Oncol 25 : 180 186.[CrossRef]
17. Chappel RJ,, Wilson KM,, Dax EM . 2009. Immunoassays for the diagnosis of HIV: meeting future needs by enhancing the quality of testing. Future Microbiol 4 : 963 982.[CrossRef]
18. Masciotra S,, McDougal J,, Feldman J,, Sprinkle P,, Wesolowski L,, Owen S . 2011. Evaluation of an alternative HIV diagnostic algorithm using specimens from seroconversion panels and persons with established HIV infections. J Clin Virol 52S : S17 S22.[CrossRef]
19. Branson B . 2015. HIV testing updates and challenges: when regulatory caution and public health imperatives collide. Curr HIV/AIDS Rep 12 : 117 126.[CrossRef]
20. Bio-Rad-Laboratories . 2011. Package insert—GS HIV Combo Ag/Ab EIA.
21. Alter HJ,, Epstein JS,, Swenson SG,, VanRaden MJ,, Ward JW,, Kaslow RA,, Menitove JE,, Klein HG,, Sandler SG,, Sayers MH,, Hewlett I,, Chernoff A , The HIV-Antigen Study Group . 1990. Prevalence of human immunodeficiency virus type 1 p24 antigen in U.S. blood donors—an assessment of the efficacy of testing in donor screening. N Engl J Med 323 : 1312 1317.[CrossRef]
22. Jurriaans S,, Back N,, Wolthers K . 2011. Ten years of HIV testing with fourth-generation assays: the Amsterdam experience. J Clin Virol 52S : S67 S69.[CrossRef]
23. Centers for Disease Control and Prevention (CDC) . 2013. Detection of acute HIV infection in two evaluations of a new HIV diagnostic testing algorithm - United States, 2011-2013. MMWR Morb Mortal Wkly Rep 62 : 489494.
24. Masciotra S,, Smith A,, Youngpairoj A,, Sprinkle P,, Miles I,, Sionean C,, Paz-Bailey G,, Johnson J,, Owen S . 2013. Evaluation of the CDC-proposed laboratory HIV testing algorithm among men who have sex with men (MSM) from five US metropolitan statistical areas using specimens collected in 2011. J Clin Virol 58S : e8 e12.[CrossRef]
25. Fransen K,, Vermoesen T,, Beelaert G,, Menten J,, Hutse V,, Wouters K,, Platteau T,, Florence E . 2013. Using conventional HIV tests on oral fluid. J Virol Methods 194 : 46 51.[CrossRef]
26. Pilcher CD,, Louie B,, Facente S,, Keating S,, Hackett J Jr,, Vallari A,, Hall C,, Dowling T,, Busch MP,, Klausner JD,, Hecht FM,, Liska S,, Pandori MW . 2013. Performance of rapid point-of-care and laboratory tests for acute and established HIV infection in San Francisco. PLoS One 8 : e80629 e80637.[CrossRef]
27. Pant Pai N,, Balram B,, Shivkumar S,, Martinez-Cajas JL,, Claessens C,, Lambert G,, Peeling RW,, Joseph L . 2012. Head-to-head comparison of accuracy of a rapid point-of-care HIV test with oral versus whole-blood specimens: a systematic review and meta-analysis. Lancet Infect Dis 12 : 373 380.[CrossRef]
28. Black V,, von Mollendorf CE,, Moyes JA,, Scott LE,, Puren A,, Stevens WS . 2009. Poor sensitivity of field rapid HIV testing: implications for mother-to-child transmission programme. BJOG 116 : 1805 1808.[CrossRef]
29. Orgenics-Ltd . 2013. Alere Determine™ HIV–1/2 Ag/Ab Combo package insert.
30. Masciotra S,, Luo W,, Youngpairoj AS,, Kennedy MS,, Wells S,, Ambrose K,, Sprinkle P,, Owen SM . 2013. Performance of the Alere Determine HIV-1/2 Ag/Ab Combo Rapid Test with specimens from HIV-1 seroconverters from the US and HIV-2 infected individuals from Ivory Coast. J Clin Virol 58( Suppl 1) : e54 58.[CrossRef]
31. Styer L,, Sullivan T,, Parker M . 2011. Evaluation of an alternative supplemental testing strategy for HIV diagnosis by retrospective analysis of clinical HIV testing data. J Clin Virol 52S : S35 S40.[CrossRef]
32. Bennett B,, Neumann D,, Fordan S,, Villaraza R,, Crowe S,, Gillis L . 2013. Performance of the new HIV-1/2 diagnostic algorithm in Florida’spublic health testing population: a review of the first five months ofutilization. J Clin Virol 58S : e29 e33.[CrossRef]
33. Manlutac A,, Giesick J,, McVay P . 2013. Identification of early HIV infections using the fourth generationAbbott ARCHITECT HIV Ag/Ab Combo chemiluminescentmicroparticle immunoassay (CIA) in San Diego County. J Clin Virol 58S : e44 e47.[CrossRef]
34. Bio-Rad-Laboratories . 2013. Package Insert—Multispot HIV-1/HIV-2 Rapid Test.
35. Karasi JC,, Dziezuk F,, Quennery L,, Forster S,, Reischl U,, Colucci G,, Schoener D,, Seguin-Devaux C,, Schmit JC . 2011. High correlation between the Roche COBAS(R) AmpliPrep/COBAS(R) TaqMan(R) HIV-1, v2.0 and the Abbott m2000 RealTime HIV-1 assays for quantification of viral load in HIV-1 B and non-B subtypes. J Clin Virol 52 : 181 186.[CrossRef]
36. Swenson LC,, Cobb B,, Geretti AM,, Harrigan PR,, Poljak M,, Seguin-Devaux C,, Verhofstede C,, Wirden M,, Amendola A,, Boni J,, Bourlet T,, Huder JB,, Karasi JC,, Zidovec Lepej S,, Lunar MM,, Mukabayire O,, Schuurman R,, Tomazic J,, Van Laethem K,, Vandekerckhove L,, Wensing AM,, Tang Y-W , International Viral Load Assay Collaboration . 2014. Comparative performances of HIV-1 RNA load assays at low viral load levels: results of an international collaboration. J Clin Microbiol 52 : 517 523.[CrossRef]
37. Lofgren SM,, Morrissey AB,, Chevallier CC,, Malabeja AI,, Edmonds S,, Amos B,, Sifuna DJ,, von Seidlein L,, Schimana W,, Stevens WS,, Bartlett JA,, Crump JA . 2009. Evaluation of a dried blood spot HIV-1 RNA program for early infant diagnosis and viral load monitoring at rural and remote healthcare facilities. AIDS 23 : 2459 2466.[CrossRef]
38. Fiscus SA,, Brambilla D,, Grosso L,, Schock J,, Cronin M . 1998. Quantitation of human immunodeficiency virus type 1 RNA in plasma by using blood dried on filter paper. J Clin Microbiol 36 : 258 260.
39. Lew J,, Reichelderfer P,, Fowler M,, Bremer J,, Carrol R,, Cassol S,, Chernoff D,, Coombs R,, Cronin M,, Dickover R,, Fiscus S,, Herman S,, Jackson B,, Kornegay J,, Kovacs A,, McIntosh K,, Meyer W,, Michael N,, Mofenson L,, Moye J,, Quinn T,, Robb M,, Vahey M,, Weiser B,, Yeghiazarian T for the TUBE Meeting Workshop Attendees . 1998. Determinations of levels of human immunodeficiency virus type 1 RNA in plasma: reassessment of parameters affecting assay outcome. J Clin Microbiol 36 : 1471 1479.
40. Havlir DV,, Bassett R,, Levitan D,, Gilbert P,, Tebas P,, Collier AC,, Hirsch MS,, Ignacio C,, Condra J,, Günthard HF,, Richman DD,, Wong JK . 2001. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA 286 : 171 179.[CrossRef]
41. Lalama CM,, Jennings C,, Johnson VA,, Coombs RW,, McKinnon JE,, Bremer JW,, Cobb BR,, Cloherty GA,, Mellors JW,, Ribaudo HJ , Group ACT, AIDS Clinical Trials Group . 2015. Comparison of three different FDA-approved plasma HIV-1 RNA assay platforms confirms the virologic failure endpoint of 200 copies per milliliter despite improved assay sensitivity. J Clin Microbiol 53 : 2659 2666.[CrossRef]
42. Abram ME,, Ferris AL,, Das K,, Quinoñes O,, Shao W,, Tuske S,, Alvord WG,, Arnold E,, Hughes SH . 2014. Mutations in HIV-1 reverse transcriptase affect the errors made in a single cycle of viral replication. J Virol 88 : 7589 7601.[CrossRef]
43. Kirchhoff F . 2010. Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses. Cell Host Microbe 8 : 55 67.[CrossRef]
44. Wei X,, Decker JM,, Wang S,, Hui H,, Kappes JC,, Wu X,, Salazar-Gonzalez JF,, Salazar MG,, Kilby JM,, Saag MS,, Komarova NL,, Nowak MA,, Hahn BH,, Kwong PD,, Shaw GM . 2003. Antibody neutralization and escape by HIV-1. Nature 422 : 307 312.[CrossRef]
45. Larder BA,, Kemp SD . 1989. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246 : 1155 1158.[CrossRef]
46. Liu TF,, Shafer RW . 2006. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 42 : 1608 1618.[CrossRef]
47. Simen BB,, Braverman MS,, Abbate I,, Aerssens J,, Bidet Y,, Bouchez O,, Gabriel C,, Izopet J,, Kessler HH,, Stelzl E,, Di Giallonardo F,, Schlapbach R,, Radonic A,, Paredes R,, Recordon-Pinson P,, Sakwa J,, St John EP,, Schmitz-Agheguian GG,, Metzner KJ,, Däumer MP , Group HIVA, 454 HIV Alphastudy Group . 2014. An international multicenter study on HIV-1 drug resistance testing by 454 ultra-deep pyrosequencing. J Virol Methods 204 : 31 37.[CrossRef]
48. Pou C,, Noguera-Julian M,, Pérez-Álvarez S,, García F,, Delgado R,, Dalmau D,, Álvarez-Tejado M,, Gonzalez D,, Sayada C,, Chueca N,, Pulido F,, Ibáñez L,, Rodríguez C,, Casadellà M,, Santos JR,, Ruiz L,, Clotet B,, Paredes R . 2014. Improved prediction of salvage antiretroviral therapy outcomes using ultrasensitive HIV-1 drug resistance testing. Clin Infect Dis 59 : 578 588.[CrossRef]
49. Lübke N,, Di Cristanziano V,, Sierra S,, Knops E,, Schülter E,, Jensen B,, Oette M,, Lengauer T,, Kaiser R . 2015. Proviral DNA as a Target for HIV-1 Resistance Analysis. Intervirology 58 : 184 189.[CrossRef]
50. Delaugerre C,, Braun J,, Charreau I,, Delarue S,, Nere ML,, de Castro N,, May T,, Marchou B,, Simon F,, Molina JM,, Aboulker JP , ANRS 138-EASIER study group . 2012. Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replication. HIV Med 13 : 517 525.[CrossRef]
51. Harrigan PR,, Montaner JS,, Wegner SA,, Verbiest W,, Miller V,, Wood R,, Larder BA . 2001. World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing. AIDS 15 : 1671 1677.[CrossRef]
52. Petropoulos CJ,, Parkin NT,, Limoli KL,, Lie YS,, Wrin T,, Huang W,, Tian H,, Smith D,, Winslow GA,, Capon DJ,, Whitcomb JM . 2000. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 44 : 920 928.[CrossRef]
53. Aitken SC,, Wallis CL,, Stevens W,, de Wit TR,, Schuurman R . 2015. Stability of HIV-1 nucleic acids in dried blood spot samples for HIV-1 drug resistance genotyping. PLoS One 10 : e0131541. [CrossRef]
54. McNulty A,, Jennings C,, Bennett D,, Fitzgibbon J,, Bremer JW,, Ussery M,, Kalish ML,, Heneine W,, García-Lerma JG . 2007. Evaluation of dried blood spots for human immunodeficiency virus type 1 drug resistance testing. J Clin Microbiol 45 : 517 521.[CrossRef]
55. Youngpairoj AS,, Masciotra S,, Garrido C,, Zahonero N,, de Mendoza C,, García-Lerma JG . 2008. HIV-1 drug resistance genotyping from dried blood spots stored for 1 year at 4°C. J Antimicrob Chemother 61 : 1217 1220.[CrossRef]
56. Ziemniak C,, Mengistu Y,, Ruff A,, Chen YH,, Khaki L,, Bedri A,, Simen BB,, Palumbo P,, Eshleman SH,, Persaud D . 2011. Use of dried-blood-spot samples and in-house assays to identify antiretroviral drug resistance in HIV-infected children in resource-constrained settings. J Clin Microbiol 49 : 4077 4082.[CrossRef]
57. Whitcomb JM,, Huang W,, Fransen S,, Limoli K,, Toma J,, Wrin T,, Chappey C,, Kiss LD,, Paxinos EE,, Petropoulos CJ . 2007. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 51 : 566 575.[CrossRef]
58. Pou C,, Codoñer FM,, Thielen A,, Bellido R,, Pérez-Álvarez S,, Cabrera C,, Dalmau J,, Curriu M,, Lie Y,, Noguera-Julian M,, Puig J,, Martínez-Picado J,, Blanco J,, Coakley E,, Däumer M,, Clotet B,, Paredes R . 2013. HIV-1 tropism testing in subjects achieving undetectable HIV-1 RNA: diagnostic accuracy, viral evolution and compartmentalization. PLoS One 8 : e67085. [CrossRef]
59. Branson BM,, Owen SM, . 2015. Human immunodeficiency virus, p 1437. In Jorgensen JH,, Pfaller MA,, Carroll KC (ed), Manual of Clinical Microbiology, 11th ed. ASM Press, Washington, DC. [CrossRef]

Tables

Generic image for table

Click to view

Table 1

Examples of HIV-1 serologic assays

Citation: Armstrong W, Guarner J, Kraft C, Caliendo A. 2016. Human Immunodeficiency Virus, p 53-68. In Hayden R, Wolk D, Carroll K, Tang Y (ed),

Diagnostic Microbiology of the Immunocompromised Host, Second Edition

. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.DMIH2-0024-2015
Generic image for table

Click to view

Table 2

Second-generation rapid HIV tests and second-generation rapid differentiation tests

Citation: Armstrong W, Guarner J, Kraft C, Caliendo A. 2016. Human Immunodeficiency Virus, p 53-68. In Hayden R, Wolk D, Carroll K, Tang Y (ed),

Diagnostic Microbiology of the Immunocompromised Host, Second Edition

. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.DMIH2-0024-2015
Generic image for table

Click to view

Table 3

FDA-approved real-time PCR tests for quantification of HIV-1 RNA

Citation: Armstrong W, Guarner J, Kraft C, Caliendo A. 2016. Human Immunodeficiency Virus, p 53-68. In Hayden R, Wolk D, Carroll K, Tang Y (ed),

Diagnostic Microbiology of the Immunocompromised Host, Second Edition

. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.DMIH2-0024-2015
Generic image for table

Click to view

Table 4

Selected assays for resistance testing

Citation: Armstrong W, Guarner J, Kraft C, Caliendo A. 2016. Human Immunodeficiency Virus, p 53-68. In Hayden R, Wolk D, Carroll K, Tang Y (ed),

Diagnostic Microbiology of the Immunocompromised Host, Second Edition

. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.DMIH2-0024-2015

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error